Alexandre Chan
National University of Singapore, SG, Singapore
Associate Professor Alex Chan is a Deputy Head (Clinical) and a tenured Associate Professor at Department of Pharmacy, Faculty of Science, National University of Singapore (NUS) and Duke-NUS Medical School, Singapore. He is also co-appointed as a Specialist Pharmacist at National Cancer Centre Singapore, and he serves as the program director for the national PGY-2 Hematology/Oncology residency program in Singapore. A board certified specialist in Pharmacotherapy and Oncology Pharmacy, Alex has authored recertification learning material for ambulatory care and pharmacotherapy specialists in Ambulatory Care Self-Assessment Program (ACSAP) and Pharmacotherapy Self-Assessment Program (PSAP). He has also authored several textbook chapters for the recent editions of Pharmacotherapy: A Pathophysiologic Approach.
As a clinician scientist, Alex has published over 160 full-length peer-reviewed manuscripts in a wide array of cancer supportive care and survivorship topics, including cancer-related fatigue, chemotherapy-associated cognitive impairment, chemotherapy-induced peripheral neuropathy, myselosuppression and chemotherapy-induced nausea and vomiting. He is also interested in pharmacoepidemiology and clinical pharmacy-related research. He provides research supervision to PharmD students, PhD students and fellows, and his research program has attracted over USD $3.0 million of competitive funding support from numerous agencies and pharmaceutical companies.
Alex is an elected Fellow of American College of Clinical Pharmacy (ACCP), and he is currently serving as the President-Elect for International Society of Oncology Pharmacy Practitioners (ISOPP). He is also an Associate Editor for the Journal of Oncology Pharmacy Practice. Alex has received numerous prestigious awards; he was a recipient of the Young Scientist Award at National University of Singapore in 2013, and a recipient of the Steven M. Grunberg Memorial Award from Multinational Association of Supportive Care in Cancer (MASCC) in 2015.